N/A N=8 Sensorimotor Imaging for Brain-Computer Interfaces
Functional Neuroimaging
Primary: Peak Activity Volume: Right D1 Attempt Movement Activity at S1 - SCI — 893.6 mm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Combining Attention and Metacognitive Training to Improve Goal Directed Behavior in Veterans With TBI
Mild Traumatic Brain Injury
Primary: Computerized Tower of London Average Time to Complete Problems/Total Time — 27.79; 26.78; 25.21; 22.44 seconds
N/A N=32 Action of Intra-auricular Topical Lidocaine on Tinnitus
Tinnitus, Subjective
Primary: Change in Visual Analogue Scale (VAS) Score — 6.3; 6.3; 5.5; 5.2 score on a scale
Phase 4 N=512 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Migraine
Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001
N/A N=24,465 A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Diabetes Mellitus, Type 2
Primary: Direct Healthcare Cost — 4247; 7009; 4319; 6535 Euro / patient-year — p=< 0.001
Phase 3 N=750 Sayana® Press Extension Study
Contraception
Primary: Occurrence of Pregnancy — 0; 0 Pregnancies per 100 women years
Phase 3 N=3,258 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Chikungunya Virus
Primary: Incidence of Solicited Adverse Events (AE) — 319; 373; 366; 124 Participants
N/A N=8 Uphill Walking as Exercise for COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: Dyspnea — 9.62; 9.12 score on a scale
N/A N=310 Home Hazard Removal Program to Reduce Falls
Accidental Falls
Primary: Number of Falls — 201; 316 falls
N/A N=205 Improving Outcomes for Emergency Department Patients With Alcohol Problems
Drinking, Alcohol
Primary: Number of Drinks Per Day as Assessed by Timeline Follow-Back (TLFB) — 0.91; 1.62 Drinks per day
Phase 2 N=29 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Colorectal Cancer · Metastatic Colorectal Cancer · RAS Wild Type Colorectal Cancer
Primary: Maximum Tolerated Dose (Phase I) of CB-839 in Combination With Panitumumab and Irinotecan Hydrochloride — 800 mg
Phase 3 N=17,604 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Overweight · Obesity
Primary: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction…
Phase 2 N=49 Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma · Untreated
Primary: 3-year Progression-free Survival (PFS) — 63 % of pts progression-free survival
N/A N=34 Inhibitory Control Adult Weight Management
Overweight and Obesity
Primary: BMI at Three Months — 34.53; 34.43 kg/m^2
Phase 2 N=397 Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Osteoarthritis of Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A Pain Score — -1.28; -1.35; -1.14; -0.96 score on a scale — p=0.850